AffiliationGeneral and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland., email@example.com
MeSHAnabolic Agents/*therapeutic use
Bone Density Conservation Agents/*therapeutic use
Fractures, Bone/complications/*prevention & control
Molecular Targeted Therapy
MetadataShow full item record
CitationEur J Clin Pharmacol. 2011 Apr;67(4):321-31. Epub 2011 Feb 16.
JournalEuropean journal of clinical pharmacology
AbstractPURPOSE: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. RESULTS: Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.
- Management of osteoporosis in rheumatoid arthritis patients.
- Authors: Hoes JN, Bultink IE, Lems WF
- Issue date: 2015 Mar
- The future of osteoporosis treatment - a research update.
- Authors: Lippuner K
- Issue date: 2012
- Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
- Authors: Reginster JY
- Issue date: 2011 Jan 1
- Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
- Authors: Ishtiaq S, Fogelman I, Hampson G
- Issue date: 2015 Jan
- [Anabolic treatment for osteoporosis: PTH treatment].
- Authors: Kaji H, Sugimoto T
- Issue date: 2006 Sep